FLT3LG and neoplasm: In situ daily administration of Flt3L for 9 days increased CD103+ DCs in AT-3 tumors, peripheral blood (PB), and lymph nodes (LN) including tumor-draining LN (TdLN) and mesenteric LN (mLN) (Fig. 1b and Supplementary Fig. 3a), in line with a recent study in lymphoma14.